Abstract
Progress in the arena of cancer immunotherapy has been immense in recent years. The fact remains that most of the cancer resections in the United States are performed by general surgeons and not oncologic specialists. A busy practice in general surgery will invariably make it difficult to keep pace with such rapid advancement. This review offers a concise summary of the major concepts and trials that have driven the immunotherapy revolution and their implications for surgeons who deliver cancer care.
MeSH terms
-
CTLA-4 Antigen / antagonists & inhibitors
-
CTLA-4 Antigen / immunology
-
Carcinoma, Hepatocellular / drug therapy
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Chemotherapy, Adjuvant
-
Gastrointestinal Neoplasms / drug therapy
-
Humans
-
Immunotherapy* / adverse effects
-
Liver Neoplasms / drug therapy
-
Melanoma / drug therapy*
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
-
Programmed Cell Death 1 Receptor / immunology
-
Skin Neoplasms / drug therapy*
Substances
-
CTLA-4 Antigen
-
CTLA4 protein, human
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor